#USA #Boston #ASGCT #OTXL #CGTxchange

Pioneering a New Era in Gene and Cell Therapy

As the landscape of medical treatments continues to evolve, a groundbreaking initiative has emerged from the collaboration between the American Society of Gene & Cell Therapy (ASGCT) and the Orphan Therapeutics Accelerator (OTXL). Their newly launched platform, CGTxchange, aims to serve as a marketplace designed specifically to reactivate promising cell and gene therapy programs that have been shelved despite their scientific validity. This development is particularly significant given that numerous effective therapies have been sidelined due to economic and regulatory pressures rather than a lack of clinical evidence.

The platform was publicly introduced during the ASGCT 2026 Annual Meeting in Boston, where it was live-demonstrated by Terry Flotte, President of ASGCT, alongside Craig Martin, CEO of OTXL. Their presentation underscored the urgent need for this marketplace, which connects shelved gene therapy assets with potential investors, sponsors, and partners ready to take them off the shelf and into further development.

According to a commentary by former FDA Deputy Commissioner Janet Woodcock, over 1,000 preclinical and clinical programs have found themselves neglected in recent years due to various fiscal and regulatory barriers. OTXL has taken significant steps to identify and evaluate over 80 of these neglected assets, proving that the actual number of such stalled therapies is likely much higher.

Dr. Terry Flotte emphasized the pressing need for platforms like CGTxchange, stating, "The cell and gene therapy field has built an extraordinary base of clinical evidence, and yet too many of those programs sit on the shelf for reasons that have nothing to do with the science." He further added that CGTxchange establishes a structured framework to connect those innovative programs with the right partners, thereby facilitating their revival.

The design of CGTxchange provides a comprehensive two-sided marketplace where funders and sponsors can discover program opportunities aligned with their goals. This initiative not only fosters innovation but also emphasizes helping patients gain access to therapies for diseases with significant unmet medical needs.

Collaboration and Early Adoption

In preparation for the launch, ASGCT and OTXL collaborated with a select group of sponsors to pilot the platform, refining the user experience based on this feedback. Initially, asset listing applications will open up to a broader audience beyond the early adopters, encompassing academic institutions, biotech companies, and non-profit organizations eager to list their shelved gene therapy programs.

A Boost for the Biotech Community

The CGTxchange platform’s aim to facilitate discounted onboarding for an initial cohort of listings signifies an eagerness to attract a diverse array of innovations. With the biomedical field constantly advancing, the introduction of this marketplace can help re-energize interest and investment in therapies that promise high impact but may have previously slipped through the cracks.

AOX is hopeful that CGTxchange will usher in a reawakening of interest in significant clinical assets that can profoundly affect healthcare. Interested parties, whether they are sponsors or funders, are encouraged to explore opportunities for engagement and collaboration, fostering an ecosystem that emphasizes continual advancement in the sector.

As CGTxchange opens its doors, it stands poised to revolutionize the approach to cell and gene therapy, serving as a beacon for neglected yet promising treatments. This initiative's success could ultimately lead to improved patient outcomes and reaffirm the critical role of innovation in medicine.

For more information about CGTxchange, visit their official website at CGTxchange.com.

About ASGCT and OTXL

The American Society of Gene & Cell Therapy (ASGCT) is the leading organization dedicated to the development and application of genetic and cellular therapies. They work globally to improve patient health through advances in gene therapy.

Orphan Therapeutics Accelerator (OTXL) aims to bridge the gap in the development of therapies for ultra-rare conditions, efficiently advancing programs that hold the promise of availability to patients who need them the most. For further insights into their efforts, explore their website at OrphanTXL.com.